Cynata Therapeutics : 17.08.24.Appendix 4E & Financial Statements

1. Details of reporting period‌

   Name of entity	Cynata Therapeutics Limited (the Company)
   ABN	98 104 037 372
   Reporting Period	Year ended 30 June 2017
   Previous Corresponding Period	Year ended 30 June 2016

2. Results for announcement to the market

   Key information‌	12 months ended 30 June 2017 $‌	12 months ended 30 June 2016 $	Increase/ (decrease) %	Amount change $
   Revenues from ordinary activities	1,843,105	1,247,397	47.76	595,708
   Loss from ordinary activities after tax attributable to members	4,553,536	4,939,471	(7.81)	385,935
   Net loss for the period attributable to members	4,553,536	4,939,471	(7.81)	385,935
   Net tangible asset/(deficiency) per share	0.112	0.063

3. Consolidated statement of profit or loss and other comprehensive income

   Refer to attached consolidated financial statements.

4. Consolidated statement of financial position‌

   Refer to attached consolidated financial statements.‌

5. Consolidated statement of cash flows‌

   Refer to attached consolidated financial statements.

6. Consolidated statement of changes in equity

   Refer to attached consolidated financial statements.

7. Dividends/Distributions‌‌

   No dividends declared in current or prior year.

8. Details of dividend reinvestment plans

   N/A

9. Details of entities over which control has been gained or lost during the period

   N/A

10. Details of associate and joint venture entities

    N/A

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

    Refer to attached consolidated financial statements.

12. Foreign entities

    Refer to attached consolidated financial statements.

13. Commentary on results for period and explanatory information

    Cynata Therapeutics Limited and its controlled entities (the Group) incurred a net loss from operations for the financial year ended 30 June 2017 of $4,553,536 (2016: $4,939,471). At 30 June 2017, the Group had a cash balance of $10,349,764 (2016: $4,879,173) and net assets of

    $13,864,596 (2016: $8,583,138). The net cash outflow from operating activities for the financial year was $4,115,408 (2016: $4,326,353). The Company's first mesenchymal stem cell (MSC) product, CYP-001, advanced to a Phase 1 clinical trial during the year for the treatment of Graft versus Host Disease (GvHD), with the first patient dosed in UK. This was a major milestone not only for Cynata, but also for regenerative medicine field globally as it is the first clinical trial in the world involving an allogenic, induced pluripotent stem cell (iPSC)-derived product. FUJIFILM Corporation of Japan took a $3.97 million stake in Cynata, as part of its strategic partnership with Cynata. Cynata also secured

    $6 million (before costs) in an equity placement from institutional and sophisticated investors, bringing the total capital raised during the year to $10 million. Additionally, the Company received an R&D Tax Incentive refund of $1.748 million. For more information, refer to the attached consolidated financial statements.

14. Audit

This report is based on accounts which have been audited and the audit report is included in the attached consolidated financial statements.

Dr. Ross Macdonald

Managing Director

24 August 2017

Dr Paul Wotton Non-Executive Chairman

Dr Ross Macdonald Managing Director/Chief Executive Officer Dr Stewart Washer Non-Executive Director

Dr John Chiplin Non-Executive Director

Mr Peter Webse Non-Executive Director

Mr Peter Webse

Level 3, 62 Lygon Street

Carlton, Victoria 3053

Tel: +61 3 9824 5254

Fax: +61 3 9822 7735

Email: admin@cynata.com

PO Box 7165

Hawthorn North, Victoria 3122

Website: www.cynata.com

Stantons International Level 2, 1 Walker Avenue‌‌

West Perth, Western Australia 6005

Automic Registry Services Level 2, 267 St Georges Terrace Perth, Western Australia 6000 Tel: +61 8 9324 2099

Fax: +61 8 9321 2337

Australian Securities Exchange Level 40, Central Park

152-158 St Georges Terrace Perth, Western Australia 6000

ASX Code

CYP

Cynata Therapeutics Limited